MTOR and neoplasm: However, studies thus far have demonstrated variable anti-tumor effects of mTOR inhibitors in cell line/xenograft models27,28,93, transgenic mouse models26 and in patients for tRCC94–96 and PEComas97, with mTOR kinase inhibitors conferring a greater benefit93 than rapalogs26 in pre-clinical studies.